1-5 of 5 results for subject:Risperidone
Librarians' tools
- Search time
- 0.177 seconds
- Solr query time
- 0.001 seconds
- Search query
- subject:Risperidone
- We searched for
- subject_t:Risperidone OR subject_ses:501195
Type
House
Session
Year
Department
Member
Primary member
Answering member
Legislative stage
Legislation
Subject
More
Publisher
To ask His Majesty's Government what steps they are taking to mitigate the current shortage of the psychotropic medication Olanzapine, Risperidone and Haloperidol following the sudden departure of two generic manufacturers from the UK market.
To ask His Majesty's Government what steps they are taking to mitigate the current shortage of the psychotropic medication Olanzapine, Risperidone and Haloperidol following the sudden departure of two generic manufacturers from the UK market.
We are aware that there have been supply constraints with olanzapine 210 milligram, 300 milligram, and 405 milligram powder and solvent for prolonged release suspension for injection. We worked with manufacturers to uplift production, and the issues were resolved in February 2024. We worked with NHS England to issue national communications containing advice on how to manage patients whilst there was a disruption to supply. We are not aware of any supply issues affecting oral presentations of olanzapine, or of any supply issues with any risperidone or haloperidol products.
To ask the Secretary of State for Health and Social Care, what research is being undertaken on the combined effects of risperidone and covid-19 vaccines; and whether that research will be published.
To ask the Secretary of State for Health and Social Care, what research is being undertaken on the combined effects of risperidone and covid-19 vaccines; and whether that research will be published.
The Department commissions research through the National Institute for Health and Care Research (NIHR). The NIHR is not currently supporting any specific research on the combined effects of risperidone and COVID-19 vaccines. The NIHR welcomes funding applications for research into any aspect of human health, including effects of COVID-19 vaccination.
To ask the Secretary of State for Health, what assessment he has made of the Medicines and Healthcare Products Regulatory Agency's advice not to use risperidone and olanzapine to treat behavioural problems in older patients with dementia; and when new guidelines will be published in managing dementia.
To ask the Secretary of State for Health, what assessment he has made of the Medicines and Healthcare Products Regulatory Agency's advice not to use risperidone and olanzapine to treat behavioural problems in older patients with dementia; and when new guidelines will be published in managing dementia.
To ask the Secretary of State for Health, pursuant to his Answer of 24th March, 419 c913W, on the Committee on Safety of Medicines, what information was assessed by the Medicines and Healthcare Products Regulatory Agency in 2002; pursuant to his Answer of 24th March, 419 c913W, on the Committee...
To ask the Secretary of State for Health, pursuant to his Answer of 24th March, 419 c913W, on the Committee on Safety of Medicines, what information was assessed by the Medicines and Healthcare Products Regulatory Agency in 2002; pursuant to his Answer of 24th March, 419 c913W, on the Committee...
To ask the Secretary of State for Health, how many NHS prescriptions for (a) Aricept, (b) Concerta XL and (c) Risperidone have been made in 2003; and what additional funds have been made available for prescription of these drugs. - Inc table.
To ask the Secretary of State for Health, how many NHS prescriptions for (a) Aricept, (b) Concerta XL and (c) Risperidone have been made in 2003; and what additional funds have been made available for prescription of these drugs. - Inc table.